Applied Genetic Technologies Corp. (NASDAQ:AGTC)’s share price rose 3% during trading on Friday . The stock traded as high as $15.84 and last traded at $15.61, with a volume of 63,511 shares changing hands. The stock had previously closed at $15.16.

AGTC has been the subject of several recent research reports. Roth Capital reissued a “buy” rating on shares of Applied Genetic Technologies Corp. in a research report on Monday, April 25th. Zacks Investment Research downgraded Applied Genetic Technologies Corp. from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 12th. Wedbush restated an “outperform” rating and set a $36.00 price target on shares of Applied Genetic Technologies Corp. in a report on Tuesday, May 10th. BMO Capital Markets started coverage on Applied Genetic Technologies Corp. in a report on Monday, April 11th. They set an “outperform” rating and a $25.00 price target for the company. Finally, Cantor Fitzgerald restated a “buy” rating and set a $32.00 price target on shares of Applied Genetic Technologies Corp. in a report on Wednesday, June 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Applied Genetic Technologies Corp. presently has an average rating of “Buy” and a consensus target price of $26.00.

The firm’s market capitalization is $282.94 million. The company has a 50 day moving average of $15.38 and a 200-day moving average of $15.29.

Applied Genetic Technologies Corp. (NASDAQ:AGTC) last announced its quarterly earnings data on Monday, May 9th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.06. During the same period last year, the company earned ($0.38) EPS. The business earned $12 million during the quarter, compared to the consensus estimate of $12.98 million. The business’s revenue was up 4125.4% compared to the same quarter last year. Analysts predict that Applied Genetic Technologies Corp. will post ($0.16) earnings per share for the current fiscal year.

A number of institutional investors have made changes to their positions in the stock. Jennison Associates LLC increased its position in shares of Applied Genetic Technologies Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 677,610 shares of the company’s stock valued at $13,823,000 after buying an additional 3,248 shares during the period. Globeflex Capital L P acquired a new position in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at approximately $1,189,000. CAM Group Holding A S acquired a new position in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at approximately $1,428,000. Finally, Russell Frank Co acquired a new position in shares of Applied Genetic Technologies Corp. during the fourth quarter valued at approximately $1,541,000.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.